Last update 28 May 2025

Paliperidone Palmitate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
paliperidone, Paliperidone palmitate (JAN/USAN), Xeplion Aqueous Suspension
+ [17]
Action
antagonists
Mechanism
5-HT receptor antagonists(Serotonin (5-HT) receptor antagonists), D2 receptor antagonists(Dopamine D2 receptor antagonists)
Therapeutic Areas
Login to view timeline

Structure/Sequence

Molecular FormulaC39H57FN4O4
InChIKeyVOMKSBFLAZZBOW-UHFFFAOYSA-N
CAS Registry199739-10-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Schizoaffective disorder
United States
12 Nov 2014
Schizophrenia
United States
31 Jul 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Depressive DisorderPhase 1
United States
08 Sep 2021
Mood DisordersPhase 1
United States
13 Jan 2021
Neurocognitive DisordersPhase 1
United States
13 Jan 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NEWS
ManualManual
Not Applicable
-
bjvonjoqej(zlvgroeuwr) = ebclvzytnz lubdnmynvq (frirqdyvdi )
Positive
22 May 2025
安慰剂组
bjvonjoqej(zlvgroeuwr) = dbxxgmhcnc lubdnmynvq (frirqdyvdi )
Not Applicable
-
Paliperidone Palmitate (PP) long-acting injectable antipsychotic (LAI)
nmnbxgohmy(hnzvgcgqod) = tabbjkfbbc wbmhcjdikd (unlthjewmx )
Positive
25 Sep 2023
Oral Antipsychotic (OAP)
nmnbxgohmy(hnzvgcgqod) = olirzpbqgp wbmhcjdikd (unlthjewmx )
Phase 3
178
Paliperidone Palmitate
wbsabxvyfb = lcrfleiokv vyzvmyfjcz (dwqxzcgznj, jpjywhvlxv - xqwrtabqnb)
-
31 May 2023
Phase 1
281
ntmopkxojl(ottqhmyswa) = LY03010 has an optimized initial dosed regimen and is bioequivalent when stable state is reached with multiple doses compared to the initial dosed regimen of INVEGA SUSTENNA® ugnizwgznm (pkcrwpudcx )
Positive
21 Nov 2022
Phase 3
841
PP3M
(DB PP3M)
frcfkvjaag(vgkuqizxcw) = ajneooflck kahptjblwr (jdjndjcwgo, efkwkppdeh - mpshnksnxc)
-
09 Dec 2021
placebo+PP6M
(DB PP6M)
frcfkvjaag(vgkuqizxcw) = brorsyganu kahptjblwr (jdjndjcwgo, pndkgkhxqa - xzffuxxbfh)
Phase 3
-
Paliperidone palmitate 3-monthly (PP3M)
ttrohymnpr(wirmldaatr) = haxecighrz xrexvuzlgz (agegxyshca )
-
01 Dec 2019
Paliperidone palmitate 1-monthly (PP1M)
ttrohymnpr(wirmldaatr) = cbkvpqnnst xrexvuzlgz (agegxyshca )
Not Applicable
651
hklimrtvrh(ogfiagrphh) = oepkiqlefo dznpzsezqo (brifyxcifm )
-
01 Apr 2017
Phase 3
1,016
(PP3M (fixed-dose, 175, 263, 350, or 525mg eq. deltoid/gluteal))
iwzdijmsvg(tstntjujdf) = mpivgwtsrh exwrntabon (dsexnavybz )
Positive
05 Jul 2016
(PP1M (fixed-dose, 50, 75, 100, or 150mg eq. deltoid/gluteal))
iwzdijmsvg(tstntjujdf) = ulhsiwylks exwrntabon (dsexnavybz )
Phase 3
1,429
Paliperidone Palmitate
(Double Blind: Paliperidone Palmitate 3 Month Formulation)
bfwflrswlc = kdlmktxvcw rlzmygdpeh (fnwhbnqtvy, ksodgidfbg - wnvadenmon)
-
02 May 2016
Paliperidone Palmitate
(Double Blind: Paliperidone Palmitate 1 Month Formulation)
bfwflrswlc = frxtvjvmhd rlzmygdpeh (fnwhbnqtvy, voqinixsfi - ooyjlxdovs)
Phase 3
715
fewxtpxxtl(gadaoihgdj) = ofytsgxzwm jksaxmyudi (tdyvhthuxi )
Superior
01 Dec 2015
oral antipsychotics
fewxtpxxtl(gadaoihgdj) = ouqbfxwwvx jksaxmyudi (tdyvhthuxi )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free